Cagrilintide
compound
Long-acting amylin analog; activates AMYR and CTR. In Phase III development. Being combined with semaglutide (CagriSema) in trials showing up to 22-25% weight loss at 32 weeks.
Updated 5/19/2026
Dulaglutide
compound
Once-weekly GLP-1 RA with IgG4-Fc fusion for extended half-life. FDA-approved for T2D and cardiovascular risk reduction. Brand name: Trulicity.
Updated 5/19/2026
Exenatide
compound
First FDA-approved GLP-1 RA. Derived from exendin-4. Available as twice-daily (Byetta) and weekly (Bydureon) formulations. Brand names: Byetta, Bydureon.
Updated 5/20/2026
Liraglutide
compound
First-generation long-acting GLP-1 analog. FDA-approved for T2D (Victoza) and obesity (Saxenda 3mg). Daily injection. Brand names: Victoza, Saxenda.
Updated 5/20/2026
Retatrutide
compound
Investigational triple agonist targeting GLP-1R, GIPR, and glucagon receptor. Phase II trials show up to 24% weight loss at 48 weeks — most powerful peptide weight loss to date.
Updated 5/19/2026
Semaglutide
compound
This research monograph provides an in-depth analysis of semaglutide, a GLP-1 receptor agonist effective for type 2 diabetes management and weight loss. It discusses its pharmacological mechanisms, clinical applications, safety profile, and emerging evidence highlighting neuroprotective effects. Furthermore, it reviews preclinical and clinical data, pointing towards various ongoing trials and the compound's evolving role in metabolic medicine.
Updated 5/20/2026
Tirzepatide
compound
FDA-approved dual incretin mimetic (GLP-1 + GIP). Demonstrated superior weight loss (~20-22%) and glycemic control versus semaglutide in head-to-head trials. Brand names: Mounjaro, Zepbound.
Updated 5/20/2026